Cencora, Inc. (NYSE:COR) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 120.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 357,956 shares of the company's stock after acquiring an additional 195,668 shares during the period. Allspring Global Investments Holdings LLC owned about 0.18% of Cencora worth $80,569,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Buckley Wealth Management LLC boosted its position in shares of Cencora by 1.5% during the 3rd quarter. Buckley Wealth Management LLC now owns 5,345 shares of the company's stock worth $1,203,000 after acquiring an additional 80 shares in the last quarter. Capital Investment Advisors LLC boosted its holdings in Cencora by 35.4% in the third quarter. Capital Investment Advisors LLC now owns 1,334 shares of the company's stock valued at $300,000 after purchasing an additional 349 shares in the last quarter. Blue Trust Inc. increased its stake in Cencora by 108.7% in the third quarter. Blue Trust Inc. now owns 2,776 shares of the company's stock valued at $625,000 after purchasing an additional 1,446 shares during the last quarter. Net Worth Advisory Group purchased a new position in Cencora in the third quarter valued at approximately $586,000. Finally, Aaron Wealth Advisors LLC raised its holdings in Cencora by 85.9% during the third quarter. Aaron Wealth Advisors LLC now owns 1,694 shares of the company's stock worth $381,000 after purchasing an additional 783 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company's stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares of the company's stock, valued at $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the firm's stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 1,473 shares of the company's stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now owns 10,948 shares in the company, valued at $2,656,970.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 15.80% of the company's stock.

Analyst Upgrades and Downgrades

COR has been the subject of several research analyst reports. Evercore ISI lowered their target price on shares of Cencora from $270.00 to $250.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Leerink Partners decreased their price objective on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research note on Monday, October 7th. Bank of America reiterated a "neutral" rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Robert W. Baird decreased their target price on Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a research report on Friday, September 6th. Finally, StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $259.44.

Cencora Stock Performance

Shares of NYSE:COR traded down $0.89 during trading on Monday, reaching $236.54. The company had a trading volume of 847,732 shares, compared to its average volume of 1,420,911. Cencora, Inc. has a fifty-two week low of $182.75 and a fifty-two week high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The stock's fifty day moving average price is $232.36 and its 200 day moving average price is $230.92. The firm has a market capitalization of $47.18 billion, a price-to-earnings ratio of 25.88, a price-to-earnings-growth ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping analysts' consensus estimates of $3.18 by $0.16. The company had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. Cencora's quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.92 EPS. As a group, equities research analysts predict that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend was Friday, August 9th. Cencora's dividend payout ratio (DPR) is 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.